Evolution of Tc-99m in diagnostic radiopharmaceuticals

被引:209
作者
Banerjee, S [1 ]
Pillai, MRA [1 ]
Ramamoorthy, N [1 ]
机构
[1] Bhabha Atom Res Ctr, Radiopharmaceut Div, Isotope Grp, Bombay 400085, Maharashtra, India
关键词
D O I
10.1053/snuc.2001.26205
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The progress in diagnostic nuclear medicine over the years since the discovery of Tc-99m is indeed phenomenal. Over 80% of the radiopharmaceuticals currently being used make use of this short-lived, metastable radionuclide, which has reigned as the workhorse of diagnostic nuclear medicine. The preeminence of Tc-99m is attributable to its optimal nuclear properties of a short half-life and a gamma photon emission of 140 keV, which is suitable for high-efficiency detection and which results in low radiation exposure to the patient. (TcO4-)-Tc-99m, which is readily available as a column eluate from a Mo-99/Tc-99m generator, is reduced in the presence of chelating agents. The versatile chemistry of technetium emerging from the 8 possible oxidation states, along with a proper understanding of the structure-biologic activity relationship, has been exploited to yield a plethora of products meant for morphologic and functional imaging of different organs. This article reviews the evolution of Tc-99m dating back to its discovery, the development of Mo-99/Tc-99m generators, and the efforts to exploit the diverse chemistry of the element to explore a spectrum of compounds for diagnostic imaging, planar, and single photon emission computed tomography. A brief outline of the Tc-99m radiopharmaceuticals currently being used has been categorically presented according to the organs being imaged. Newer methods of labeling involving bifunctional chelating agents (which encompass the "3 + 1" ligand system, Tc(CO)(3)(+1)-,containing chelates, hydrazinonicotinamide, water-soluble phosphines, and other Tc-carrying moieties) have added a new dimension for the preparation of novel technetium compounds. These developments in technetium chemistry have opened new avenues in the field of diagnostic imaging. These include fundamental aspects in the design and development of target-specific agents, including antibodies, peptides, steroids, and other small molecules that have specific receptor affinity. Copyright (C) 2001 by W.B. Saunders Company.
引用
收藏
页码:260 / 277
页数:18
相关论文
共 246 条
[91]   Potential technetium small molecule radiopharmaceuticals [J].
Jurisson, SS ;
Lydon, JD .
CHEMICAL REVIEWS, 1999, 99 (09) :2205-2218
[92]   99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent [J].
Karra, SR ;
Schibli, R ;
Gali, H ;
Katti, KV ;
Hoffman, TJ ;
Higginbotham, C ;
Sieckman, GL ;
Volkert, WA .
BIOCONJUGATE CHEMISTRY, 1999, 10 (02) :254-260
[93]   Design and development of functionalized water-soluble phosphines: Catalytic and biomedical implications [J].
Katti, KV ;
Gali, H ;
Smith, CJ ;
Berning, DE .
ACCOUNTS OF CHEMICAL RESEARCH, 1999, 32 (01) :9-17
[94]  
Katzenellenbogen JA, 1997, ANTICANCER RES, V17, P1573
[95]  
KELLY JD, 1993, J NUCL MED, V34, P222
[96]  
KELLY JD, 1990, TECHNETIUM RHENIUM C, V3, P405
[97]  
KHAW BA, 1993, J NUCL MED, V34, P2264
[98]  
Kipper SL, 2000, J NUCL MED, V41, P449
[99]  
Kniess T, 1998, J LABELLED COMPD RAD, V41, P605
[100]   TC-99M LABELED BIOTIN CONJUGATE IN A TUMOR PRETARGETING APPROACH WITH MONOCLONAL-ANTIBODIES [J].
KOCH, P ;
MACKE, HR .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1992, 31 (11) :1507-1509